Latest news with #DivisLaboratories
Business Standard
24-05-2025
- Business
- Business Standard
Divis Lab enters into a LT manufacturing and supply agreement with a global pharma co.
Divis Laboratories has entered into a long term manufacturing and supply agreement with a global pharma company. Under this agreement, the Company will be manufacturing and supplying advanced intermediates as per the commercial terms agreed between the parties. The Company expects meaningful revenue contribution from this long-term agreement. Cost of capacity addition for manufacturing under this agreement is estimated to be Rs.650-750 crore, which will be funded from the capacity reservation advance proposed to be paid by the customer phase wise under this Agreement.
Business Standard
24-05-2025
- Business
- Business Standard
Divis Lab inks long-term global pharma deal
Divis Laboratories has announced the signing of a long-term manufacturing and supply agreement with a global pharmaceutical company. As part of the agreement, Divis will manufacture and supply advanced pharmaceutical intermediates to the global partner. The company has stated that the contract is expected to contribute meaningfully to its revenue over the long term. To support the execution of this deal, Divis plans to invest between Rs 650 crore and Rs 750 crore to expand its manufacturing capacity. This investment will be funded through capacity reservation advances that will be paid in phases by the customer. Divis Laboratories believes the partnership will not only ensure a reliable supply chain for the customer but also allow the company to strengthen its foothold in the custom synthesis space. The company clarified that the deal does not involve any share exchange or related party transactions. There is no involvement of the promoter group or affiliated companies in the agreement. Divis Laboratories is engaged in the manufacture of active pharmaceutical ingredients, intermediates and nutraceutical ingredients. The company's consolidated net profit jumped 23.04% to Rs 662 crore while revenue from operations grew by 12.24% to Rs 2,585 crore in Q4 March 2025 over Q4 March 2024.
Reuters
19-05-2025
- Business
- Reuters
Indian share benchmarks set for muted start after US rating downgrade
May 19 (Reuters) - India's equity benchmark indexes are likely to open little changed on Monday, as global investor sentiment was dented after Moody's downgraded U.S. government's credit rating on Friday. The Gift Nifty futures were trading at 25,066.5 as of 8:10 a.m. IST, indicating that the Nifty 50 (.NSEI), opens new tab will open around its previous close of 25,019.8. Most Asian markets were lower on the day, with MSCI Asia ex Japan (.MIAPJ0000PUS), opens new tab down 0.7%, while U.S. equity futures and the dollar also slipped. U.S. Treasury yields rose on Friday after rating agency Moody's downgraded the U.S. government to AA1 from AAA, citing rising debt and interest "that are significantly higher than similarly rated sovereigns". Higher Treasury yields make bonds attractive for foreign portfolio investors, which does not bode well for equities in emerging markets such as India. Investors will closely watch if the rising yields trigger any change in the course of foreign flows. Foreign portfolio investors bought Indian shares worth 159.25 billion rupees ($1.9 billion) last week, when the Nifty 50 gained 4.2%. This was the fifth consecutive weekly buying from these investors. Traders are waiting for news on India-U.S. trade talks after U.S. President Donald Trump said last week that India has offered a trade deal with zero tariffs. ** Divi's Laboratories ( opens new tab posts higher profit, opens new tab and revenue for the fourth quarter, with analysts attributing the growth to generic active pharmaceutical ingredients ** Dr Reddy's Laboratories ( opens new tab says U.S. Food and Drug Administration completed inspection, opens new tab at its New York facility and issued a form 483 with two observations ** Bharat Electronics ( opens new tab says it received orders worth 5.72 billion rupees since the last disclosure on April 7
Business Standard
17-05-2025
- Business
- Business Standard
Divis Lab Q4 PAT climbs 23% YoY to Rs 662 cr; recommends final dividend of Rs 30/ share
The pharma major's consolidated net profit jumped 23.04% to Rs 662 crore in Q4 FY25 as against Rs 538 crore recorded in Q4 FY24. Revenue from operations grew by 12.24% year on year (YoY) to Rs 2,585 crore in the quarter ended 31 March 2025. Profit before tax for the quarter was at Rs 864 crore, up 21.17% from Rs 713 crore reported in the same period a year ago. Total expense stood at Rs 1,807 crore in Q4 FY25, up 8.26% on a YoY basis. The cost of material consumed was Rs 931 crore (up 3.67% YoY) and employee benefit expenses stood at Rs 350 crore (up 17.84% YoY) during the period under review. The company reported a forex gain of Rs 10 crore in Q4 FY25, compared to a loss of Rs 2 crore in Q4 FY24. On a standalone basis, the companys net profit surged 25.61% to Rs 667 crore on a 12.26% rise in revenue to Rs 2,536 crore in Q4 FY25 over Q4 FY24. For the financial year ended 31 March 2025, the companys consolidated net profit rose 36.93% YoY to Rs 2,191 crore. Revenue from operations grew 19.31% YoY to Rs 9,360 crore, compared to FY24. On the capex front, the company stated that the Unit III greenfield project at Ontimamidi Village, near Kakinada, Andhra Pradesh, commenced commercial operations during the current quarter. The company capitalised assets worth Rs 1,118 crore during the financial year, of which Rs 755 crore pertained to Unit III at Kakinada. Meanwhile, the companys board has recommended a dividend of Rs 30 per equity share for the financial year 202425, subject to approval by the members at the upcoming Annual General Meeting. Further, the companys board has approved the superannuation of L. Kishore Babu, Chief Financial Officer and Key Managerial Personnel, effective from 1 August 2025. The board placed on record its appreciation for Babus contributions and leadership at Divis Labs. Furthermore, the board has approved the appointment of Venkatesa Perumallu Pasumarthy as chief financial officer and key managerial personnel, also effective 1 August 2025. The appointment was recommended by the Nomination and Remuneration Committee and the Audit Committee of the company. Divis Laboratories is engaged in the manufacture of active pharmaceutical ingredients, intermediates and nutraceutical ingredients. Shares of Divis Laboratories gained 1.16% to end at Rs 6,281.35 on Friday, 16 May 2025.
Business Standard
24-04-2025
- Business
- Business Standard
Divis Lab spurts as broker maintains buy call
Divis Laboratories surged 5.35% to Rs 6234.50 after a leading foreign brokerage maintained its 'Buy' rating on the stock, setting a price target of Rs 7,050 per share. In its latest note, the broker highlighted Divis strong potential to emerge as a primary supplier, backed by ongoing capacity expansion. It also noted the addition of OrforglipronEli Lillys promising oral GLP-1 candidateto Divis development pipeline. The report further anticipates additional rounds of capital expenditure as product volumes scale up through 2030. Divi's is engaged in manufacturing of generic APIs, custom synthesis of active ingredients for innovator companies, other specialty chemicals and nutraceuticals. The company is focused on export markets within the domain of its capabilities. Divis Laboratories' consolidated net profit surged 64.53% to Rs 589 crore on 25.01% rise in revenue from operations to Rs 2,319 crore in Q3 FY25 over Q3 FY24.
